Monday, 15 February 2021

Hemophilia Treatment Market Size, Share, Outlook, and Opportunity Analysis, 2019– 2027

 

Global Hemophilia Treatment Market, by Product Type (Plasma Derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Antifibrinolytic Agents, and Desmopressin), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), was valued at US$ 11,474.3 million in 2018, and is expected to exhibit a CAGR of 5.9%, over the forecast period (2019-2027).

Increasing incidence & prevalence of hemophilia or factor VIII deficiency is expected to drive growth of the hemophilia treatment market over the forecast period. For instance, according to the World Federation of Hemophilia (WFH), around 440,000 people across the globe were suffering from hemophilia, out of which around 173,000 people were diagnosed with hemophilia A or B in 2017. Major players are focused on product launches and approvals owing to the rising demand for hemophilia treatment. For instance, in March 2016, the U.S. Food and Drug Administration approved Kedrion’s Koate Double Viral Inactivation (DVI) Antihemophilic Factor (human) with Mix2Vial, for treatment of factor VIII deficiency. Moreover, in May 2018, Chugai Pharmaceutical Co., Ltd., a subsidiary of Roche Group launched its anticoagulation factor IXa/X humanized biospecific monoclonal antibody/coagulation factor VIII substitute, HEMLIBRA, for routine prophylaxis, to prevent or reduce the frequency of bleeding episodes in patients with congenital factor VIII deficiency (hemophilia A) with factor VIII inhibitors.

* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.

Request a sample copy of this report: https://www.coherentmarketinsights.com/insight/request-sample/2012

Browse 35 Market Data Tables and 21 Figures spread through 188 Pages and in-depth TOC on 'Hemophilia Treatment Market’- global forecast to 2027, by Product Type (Plasma Derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Antifibrinolytic Agents, and Desmopressin), by Disease Indication (Hemophilia A, Hemophilia B, and Hemophilia C), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)'

Asia Pacific is expected to offer lucrative growth opportunities for players operating in the hemophilia treatment market owing to the favorable regulatory scenario and guidelines by government authorities, which, in turn, is expected to fuel growth of the market over the forecast period. For instance, according to the World Hemophilia Foundation’s 2015 report of National Tenders for Purchase of Clotting Factor Concentrates, According to the Chinese Ministry of Health report 2012, in China, outpatient hemophilia treatment is covered by health insurance schemes in more than 80% of the cities in China, with reimbursement caps and patient co-pay requirements more than 50%. Moreover, annual reimbursement is usually capped below US$ 16,000. Moreover, several major players in the market are focusing on collaborations with the aim of developing novel therapies for factor VIII deficiency treatment, which is expected to facilitate growth of the market over the forecast period. For instance, in August 2018, RCSI, a Dublin-based international health sciences institution, and Bayer AG entered a research collaboration to develop new treatment options for people with severe hemophilia. Furthermore, in May 2017, Sangamo Therapeutics, Inc., a genomic medicine company, and Pfizer Inc., entered a global collaboration and license agreement for development and commercialization of a gene therapy-based product for treatment of hemophilia A.

Browse Research Report: https://www.coherentmarketinsights.com/market-insight/hemophilia-treatment-market-2012

Key Takeaways of the Hemophilia Treatment Market:

The global hemophilia treatment market is expected to exhibit a CAGR of 5.9% over the forecast period owing to rising incidence of hemophilia, and approvals and launch of novel products. For instance, according to the National Hemophilia Foundation’s 2018 report, globally one in 10,000 people are born with hemophilia A due to deficiency of clotting factor VIII, and one in 50,000 people are born with hemophilia B due to lack of clotting factor IX.

Among product type, the plasma derived coagulation factor concentrates segment held a dominant position in the hemophilia treatment market in 2018 owing to cost effectiveness. For instance, according to the reports published by the World Federation of Hemophilia in 2016, the demand for plasma derived coagulation factors is high compared to recombinant coagulation concentrates due to their affordability and easy availability in emerging economies.

Companies operating in the global hemophilia treatment market include Takeda Pharmaceutical Co., Ltd., Sanofi S.A., Octapharma AG, Swedish Orphan Biovitrum AB, Baxter International Inc., Biogen Inc., Bayer AG, CSL Behring, Ferring B.V., Pfizer, Inc., Kedrion, Novo Nordisk A/S, F. Hoffmann-La Roche AG.

Buy-Now this research report: https://www.coherentmarketinsights.com/insight/buy-now/2012

About Coherent Market Insights:            

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

mailto:sales@coherentmarketinsights.com

U.S. Office:

Name:  Mr. Shah

Coherent Market Insights 1001 4th Ave,

# 3200 Seattle, WA 98154, U.S.

US :  +1-206-701-6702

UK :  +44-020-8133-4027

JAPAN :  +050-5539-1737


No comments:

Post a Comment